We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+17.17%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.6B
AUM Growth
+$255M
Cap. Flow
-$1.97M
Cap. Flow %
-0.08%
Top 10 Hldgs %
27.03%
Holding
158
New
8
Increased
60
Reduced
24
Closed
11

Top Buys

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$19.4M
2
UNH icon
UnitedHealth
UNH
+$19.2M
3
WST icon
West Pharmaceutical
WST
+$14.7M
4
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$12.2M
5
ARGX icon
argenx
ARGX
+$11.5M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.1M
2
AET
Aetna Inc
AET
+$40.4M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$23.5M
4
PRAH
PRA Health Sciences, Inc.
PRAH
+$9.19M
5
ZTS icon
Zoetis
ZTS
+$8.44M

Sector Composition

Rank Sector Weight
1 Healthcare 89.28%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
YARW
126
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$2.68M 0.1%
92
– –
ACET icon
127
Adicet Bio
ACET
$74.7M
$2.52M 0.1%
2,455
– –
NBRV
128
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.23M 0.09%
2,560
+60
+2% +$68.7K
MCRB icon
129
Seres Therapeutics
MCRB
$48.4M
$1.89M 0.07%
11,000
– –
KNSA icon
130
Kiniksa Pharmaceuticals
KNSA
$5.93B
$1.56M 0.06%
+90,000
New +$1.63M
CDTX
131
DELISTED
Cidara Therapeutics
CDTX
$1.56M 0.06%
15,000
– –
BCRX icon
132
BioCryst Pharmaceuticals
BCRX
$2.4B
$1.43M 0.06%
250,000
-675,000
-73% -$3.72M
SCYX icon
133
SCYNEXIS
SCYX
$52M
$1.34M 0.05%
10,250
– –
KA
134
DELISTED
Kineta, Inc. Common Stock
KA
$1.31M 0.05%
3,367
-1,454
-30% -$910K
PRTA icon
135
CALL
Prothena Corp
PRTA
$450M
$1.24M 0.05%
85,000
-50,000
-37% -$988K
CHMA
136
DELISTED
Chiasma, Inc. Common Stock
CHMA
$788K 0.03%
525,000
– –
MCK icon
137
McKesson
MCK
$101B
$667K 0.03%
+5,000
New +$731K
BMY icon
138
Bristol-Myers Squibb
BMY
$132B
– –
-650,000
Closed -$41.1M
DBVT
139
DBV Technologies
DBVT
$847M
– –
-7,300
Closed -$1.68M
MRUS
140
DELISTED
Merus
MRUS
– –
-174,917
Closed -$3.24M
PRTA icon
141
Prothena Corp
PRTA
$450M
– –
-318,500
Closed -$6.29M
TXMD icon
142
TherapeuticsMD
TXMD
$24M
– –
-23,456
Closed -$5.71M
ZTS icon
143
Zoetis
ZTS
$30B
– –
-101,000
Closed -$8.44M
INFI
144
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-270,000
Closed -$567K
AIMT
145
DELISTED
Aimmune Therapeutics
AIMT
– –
-160,000
Closed -$5.09M
AET
146
DELISTED
Aetna Inc
AET
– –
-239,000
Closed -$40.4M
AVXS
147
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-190,000
Closed -$23.5M
SHPG
148
DELISTED
Shire pic
SHPG
– –
-37,500
Closed -$5.6M
2 3 4 5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Rock Springs Capital Management held 158 positions worth $2.6B, up 11% from $2.34B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q2 2018 filing shows 8 new, 60 increased, 24 reduced and 11 closed positions. Its largest new stake was West Pharmaceutical: 160,000 shares worth $15.9M. The largest sale was Bristol-Myers Squibb, an estimated $41.1M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 88% a quarter earlier, followed by Financials.

  • Rock Springs Capital Management's largest Q2 2018 buy was West Pharmaceutical: 160,000 shares worth $15.9M.
  • Rock Springs Capital Management added most to Wellcare Health Plans, Inc. in Q2 2018, an estimated $19.4M increase.
  • Rock Springs Capital Management's biggest Q2 2018 reduction was PRA Health Sciences, Inc., cutting an estimated $9.19M.
  • Rock Springs Capital Management fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $41.1M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $2.6B portfolio in Q2 2018.
  • Rock Springs Capital Management opened 8 new positions and closed 11 in Q2 2018.
  • Rock Springs Capital Management's portfolio value rose 11% quarter-over-quarter to $2.6B.

Based on Rock Springs Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.